Idiopathic Pulmonary Fibrosis

July 25, 2017July 25, 2017

ZappRx Implements Specialty Medication Prescribing Platform at 2 Pulmonary Medical Centers

Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Harbor-UCLA Medical Center in Torrance, California, and Phoenix-based Arizona Pulmonary Specialists — the largest U.S. private practice treating pulmonary hypertension — now offer a digital platform designed by ZappRx to facilitate the complex ... Read more

July 24, 2017July 24, 2017

Real-world Safety of Ofev and Esbriet Matches Trial Reports, Despite Office Patients Older, Sicker

Idiopathic Pulmonary Fibrosis, News

Patients treated with Ofev (nintedanib) or Esbriet (pirfenidone) for pulmonary fibrosis in a real-world setting have similar rates of side effects as those reported in clinical trials testing the drugs, despite ... Read more

July 20, 2017July 20, 2017

Samumed Completes Phase 1 Study of Potential IPF Treatment with Positive Results

Idiopathic Pulmonary Fibrosis, News

Samumed has successfully completed a Phase 1 clinical trial in healthy individuals to evaluating a potential therapy — a nebulized inhalation solution called SM04646 — that treats idiopathic pulmonary fibrosis (IPF). The positive ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

Idiopathic Pulmonary Fibrosis, News

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

July 14, 2017July 14, 2017

Researchers Identify a Type of Immune Cells that Contribute to Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

Certain immune cells, called monocyte-derived alveolar macrophages, may contribute to lung inflammation and fibrosis, according to the results of a new study. Researchers believe that therapies targeting these monocyte-derived macrophages may ... Read more

July 6, 2017July 6, 2017

Study Supports the Development of Envisia Genomic Classifier for IPF Diagnosis

Idiopathic Pulmonary Fibrosis, News

Veracyte recently announced that results from a study supporting the development of the Envisia Genomic Classifier, a genomic test used to improve the diagnosis of idiopathic pulmonary fibrosis (IPF), have been ... Read more

July 5, 2017July 5, 2017

Respiratory Hospitalization Rates May Improve Outcome Assessments in IPF Trials, Researchers Suggest

Idiopathic Pulmonary Fibrosis, News

Researchers at Columbia University propose that respiratory-related hospitalization rates are an important “patient-centered” outcome measure that should be considered in clinical trials assessing treatment effectiveness in patients with idiopathic pulmonary fibrosis (IPF), ... Read more

June 30, 2017June 30, 2017

New Esbriet Tablets for IPF Treatment Now Available in Europe

Idiopathic Pulmonary Fibrosis, News

The European Commission has approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Esbriet, developed by Roche, is an oral antifibrotic medication approved ... Read more

June 29, 2017June 29, 2017

Traditional Chinese Medicine Therapy Can Help Slow PF Progression, Study Finds

Idiopathic Pulmonary Fibrosis, News

Pulmonary rehabilitation mixture (PRM), an herbal-based formula used for decades in Chinese traditional medicine, has therapeutic potential against pulmonary fibrosis (PF) progression by targeting several molecular factors known to be involved ... Read more

June 28, 2017June 28, 2017

Washington University to Sequence DNA of Lung Disease Patients Across Ethnic Groups

COPD, Idiopathic Pulmonary Fibrosis, News

The McDonnell Genome Institute at Washington University has received a $10 million U.S. government grant to map the DNA of patients from a number of ethnic groups who had chronic obstructive pulmonary disease ... Read more